Transcatheter aortic valve implantation (TAVI) has become a well‐established therapeutic option for patients with severe aortic stenosis (AS) at high to intermediate surgical risk. Although TAVI is associated with low… Click to show full abstract
Transcatheter aortic valve implantation (TAVI) has become a well‐established therapeutic option for patients with severe aortic stenosis (AS) at high to intermediate surgical risk. Although TAVI is associated with low mortality of 1.2–6.5%, cardiogenic shock (CS) as a peri‐interventional complication remains a challenging problem with very high morbidity and mortality.
               
Click one of the above tabs to view related content.